









Qurient Therapeutics

2020 Investor Relations

Innovation for Unmet Medical Needs

DISCLAIMER

This presentation has been prepared by Qurient Co., Ltd. (hereinafter "the Company"), with an aim to provide investors with the latest information about the Company.
The presentation may not be reproduced in whole or in part, nor may any of its contents be divulged to any third party without prior consent by the Company.

The accuracy of the 'forward-looking statements' included in this presentation has not been independently verified. The forward-looking statements include projections and outlook of the Company concerning its business status and financial results, and include but not limited to words such as 'expectation', 'forecast', 'plan', 'anticipation', '(F)' or '(E)'. The forward-looking statements are subject to changes in business environment and involve inherent risks and uncertainties. We caution you that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statements.

Furthermore, any future expectations are based on current business environment and the Company's management direction as of the date of presentation. Future projections may differ or change due to changes in business environment or due to strategic changes by the Company. The contents in this presentation may change without any prior notification. None of the Company nor its respective officers assume legal responsibility for any damages or losses that may have occurred from the use of this presentation, including errors and other mistakes that may be included in this presentation.

This presentation does not constitute or form a part of an offer or solicitation to purchase or subscribe for securities for sale, and any information included in this presentation may not be used as a basis for related contracts, subscriptions or investment decisions.

CONTENTS

Company Overview
at a Glance

Company Profile

Company Name	Qurient Co., Ltd.
CEO	Kiyean Nam, Ph.D
Established	02 July 2008
IPO	26 February 2016 (Kosdaq Listed)
Capital	4.9 billion won (as of Dec. 2019)
Employees	25 (as of Dec. 2019)
Location	Seongnam-si, Gyeonggi-do, Korea
Business Area	Research and Development of Medicine



Shareholder (as of Mar. 2020)



Business Model



CONTENTS

Immuno-oncology Program

Q702

Cancer immunotherapy's Unmet Medical Needs

Immune check point inhibitor : Low Patient Response Rate







Payer's Dilemma : High cost & Low Response Rate



Immuno-oncology Program

Q702

Mechanism of Action

Suppressed TME

- ✓ Tumor promoting M2 macrophage & MDSC recruitment
- ✓ Decreased antigen presenting by loss of MHC I on cancer cell
- ✓ Decreased cytotoxic CD8 T cells



Changed TME by Q702

- ✓ Decreased Myeloid cell
- ✓ Decreased M-MDSC population
- ✓ Decreased tumor associated macrophage
- ✓ Decreased M2 population
- ✓ Increased M1 population
- ✓ Increased CD4 and CD8 T cells
- ✓ Increase antigen presenting by MHC I of cancer cell

Q702 : Axl/Mer/CSF1R Triple Inhibitor

Change of TME(tumor micro-environment) by Q702

M1 MΦ ↑ , CD8 T cell ↑ , MHC1 ↑ , M2 MΦ ↓ , MDSC ↓

Immuno-oncology Program

Q702

Key Data





Q702's Differentiation

Well poised for mono or combination immune therapy





Immuno-oncology Program

Q702

R&D Development plan

Development Status

- Nov. 2019 : US FDA Pre-IND meeting
- Apr. 2020 : US FDA clinical phase 1 IND submission
- May. 2020 : US FDA clinical phase 1 IND approval
- The second half of 2020
  - Entry of clinical phase 1 study, as monotherapy
  - Target 80 patients with advanced solid tumors, which have not responded to or have recurred following treatment with standard of care therapies
  - Dose determination & Confirmation anticancer effect

development plan

- Expansion of indications (Mono-therapy & Combi-therapy)
  - Cancer and Resistant Cancer of which immune checkpoint inhibitor do not work well
- Partnering with early Clinical Data

CONTENTS

Q901

Indications and Unmet Needs

Ovarian Cancer





- Representative female cancer that is difficult to diagnose early (Silent Killer)
- High recurrence rate after treat as standard of care therapy (25% within a year)

Prostate Cancer



The International Gynecologic Cancer Society (IGCS)



- The second highest number of patients and deaths (US standard)
- Castrate-Resistant Prostate Cancer (CRPC)

Need a treatment that shows synergy through the combination of immunotherapy and hormone therapy

Q901
Mechanism of Action

Q901 : Selective CDK7 Inhibitor



CDK7 is the Master cell cycle regulator

Q901 is an extremely selective and potent CDK7 inhibitor

Oncology Program

Q901

Key Data

High Grade Serous Ovarian Cancer



Castration Resistant Prostate Cancer



Oncology Program

Q901

R&D Development plan

Development Status

- 2020, Nomination of PCC(Preclinical Candidate)
- Developing anticancer drug about cancer associated with sex hormone such as ovarian cancer, prostate cancer, breast cancer
- Posted 2020 AACR(American Association for Cancer Research)

development plan

- 2021, Plan to enter US FDA clinical phase 1 study
  : Dose determination & Confirmation anticancer effect
- Expansion of indications

CONTENTS

Q301
Atopic Dermatitis Market

Atopic Dermatitis Market Size & Forecast

Source : Global Data, Hi Investment & Securities Research Center

Atopic Dermatitis Patients (as of 2017, 7 advanced countries)



Source : Global Data, Hi Investment & Securities Research Center

Q301

Competitive Pipeline in Global

MoA	Product	Company	Target Patient	Character	Cost Benefit
Steroid	Various	Various	Moderate to Severe	Prohibit Prescription over 1weeek Because of Side effect	Reasonable price
Calcineurin inhibitor	Protopic (tacrolimus) Elidel (pimecrolimus)	LEO Pharma Bausch Health	Moderate to Severe	"Black Label" Warning carcinogenesis of Kids	High production cost
IL4/IL13 inhibitor	Dupixent	Regeneron/Sanofi	Severe	High Price Injection	High price ($1,500 per Syringe)
PDE4 inhibitor	Eucrisa (crisaborole)	Pfizer	Mild to Moderate	First mover of nonsteroidal external preparation	High price ($650 per Tube)
Leukotriene Synthesis Inhibitor	**Q301**	**Qurient**	**Mild to Moderate**	**Proven safety by over 20 years prescription for Oral asthma drug**	**Reasonable cost similar with steroid**

New opportunity from '**Zyflo**(Zileuton)'
Drug Repositioning

Efficacy(Zileuton) + **Safety**(Cream) + **Economic**

= To require Safe and economic treatment for Infant and Kids who is major patients of AD

Clinical Program

Q301

R&D Development plan

Discovery | Candidate | Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | Approval & marketing

Qurient Therapeutics

FDA U.S. FOOD & DRUG ADMINISTRATION

Phase 2b Data

Q301, Present clinical phase 3 study strategy as a result of good clinical phase 2b study

- Confirm efficacy with 4-6 weeks dose
- Present design about phase 3 study through the result of EASI-75 and NRS
- Be comparable with Dupixent 16-week dosage result

	EASI-75	*NRS*
SOLO2(n=708, 16w)	*44%*	*-44.3%*
Q301 (n=260, 8w)	*37%*	*-52.3%*





CONTENTS

Clinical Program

Telacebec(Q203)

R&D Background

Unmet medical Needs

- **Standard Regimen : Resistant Risk ↑**
  - 4 drugs (Isoniazid, Rifampin etc.), 6 months

- **WHO treatment guideline for MDR-TB**
  - long-term medication for 18~20 months (Including 3 of levofloxacin, moxifloxacin, Bedaquiline, linezolid)
  - No Regimen with New MDR-TB drugs

WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis
2018 update

- **New Regimen using TDR-TB drug development**



- **Universal Regimen shorten treatment period needs**

TB	MDR-TB
1~2 weeks	3~4 months

Telacebec : **Front runner** of New Regimen

R&D Background

- **New MoA inhibiting Cytochrome BC1 complex**



- **Effect only on TB Less side effect**



- **Potential TDR-TB drug : Telacebec**

Isolate Type	INH	RFP	OFX	MXF	LEV	SM	KM	CPM	AMK	EMB	PTH RIF	CS	PAS	PZA	Q203 MIC_{50} (nM)
TDR02	R	R	R	R	R	R	R	R	R	R	R	R	R	R	0.6
TDR26	R	R	R	R	R	R	R	R	R	R	R	S	R	R	0.7
TDR27	R	R	R	R	R	R	R	R	R	R	R	S	R	R	2.0
TDR32	R	R	R	R	R	R	R	R	R	R	R	S	R	R	1.0
TDR41	R	R	R	R	R	R	R	R	R	R	R	R	R	R	0.1
TDR51	R	R	R	R	R	R	R	R	R	R	R	R	R	R	1.6
TDR58	R	R	R	R	R	S	R	R	R	R	R	S	S	R	0.8

INH : Isoniazid, RBP : Rifampicin, OFX : Ofloxacin, MXF : Moxifloxacin, LEV : Levofloxacin, SM : Streptomycin, KM : Kanamycin, CPM : Capreomycin, AMK : Amykacin, EMB : Ethambutol, PTH : Prothionamide, CS : Cycloserine, PAS : para-aminosalicylic acid, PZA : Pyrazinamide R : Reuastant S : Sensitive TDR: Totally drug resistant

First in Class Drug Candidate
that can solve efficacy & side effect at the same time

Clinical Program

Telacebec (Q203)

R&D Development plan

Discovery → Candidate → Preclinical → Phase 1 → Phase 2a → Phase 2b → Approval & marketing → Phase 3

한국파스퇴르연구소

FDA U.S. FOOD & DRUG ADMINISTRATION

Phase 2a Data

Telacebec(Q203) shows the most distinct anti-tuberculosis efficacy among the treatments developed to date in clinical phase 2a



Orphan Drug	Fast Track	Accelerated Approval	Priority Review Voucher *
(2015.12.18)	(2018.11.17)	after Phase 2b	after Conditional Approval

*** Priority Review Voucher (PRV)**

- 2007 US FDA, issue new PRV law for pharmaceutical companies to promote orphan drug development
- in case to develop Orphan / Inveterate disease drug, Short FDA review period within 6 month for any other new drug. Include MDR-TB drug
- Granted 34 worldwide so far

Telacebec (Q203)

Superiority

Tuberculosis

- Nature Medicine (2013.08.04)


LETTERS

nature medicine

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

Kevin Pethe[1,12], Pablo Bifani[2,12], Jichan Jang[1], Sunhee Kang[1], Seijin Park[1], Sujin Ahn[1], Jan Jiricek[2], Juyoung Jung[2], Hee Kyoung Jeon[2], Jonathan Cechetto[1], Thierry Christophe[1], Honggun Lee[1], Marie Kempf[4], Mary Jackson[5], Anne J Lenaerts[5], Ha Pham[5], Victoria Jones[5], Min Jung Seo[1], Young Mi Kim[1], Mooyoung Seo[1], Jeong Jea Seo[1], Dongsik Park[1], Yoonae Ko[1], Inhee Choi[1], Ryangyeo Kim[1], Se Yeon Kim[1], SeungBin Lim[1], Seung-Ae Yim[1], Jiyoun Nam[2], Hwankyu Kang[2], Haejin Kwon[2], Chun-Taek Oh[1], Yoojin Cho[1], Yunhee Jang[1], Junghwan Kim[1], Adeline Chua[2], Bee Huat Tan[3], Mahesh B Nanjundappa[3], Srinivasa P S Rao[3], Whitney S Barnes[6], René Wintjens[7], John R Walker[6], Sylvie Alonso[8], Saeyeon Lee[1], Jungjun Kim[8], Soohyun Oh[9], Taegwon Oh[10], Ulf Nehrbass[2], Sung-Jun Han[1], Zaesung No[1,11], Jinhwa Lee[2], Priscille Brodin[2], Sang-Nae Cho[10], Kiyean Nam[3] & Jaeseung Kim[1]

- The New England Journal of Medicine (2020.03.26)


The NEW ENGLAND JOURNAL of MEDICINE

SUBSCRIBE OR RENEW

This article is available to subscribers. Subscribe now. Already have an account? Sign in

CORRESPONDENCE FREE PREVIEW

Telacebec (Q203), a New Antituberculosis Agent

Telacebec (Q203) is a novel drug that targets *Mycobacterium tuberculosis* cellular energy production through inhibition of the mycobacterial cytochrome bc1 complex. This proof-of-concept study evaluated the bactericidal activity of telacebec over a period of 14 days in patients with newly diagnosed, drug-susceptible pulmonary tuberculosis.

March 26, 2020
N Engl J Med 2020; 382:1280-1281
DOI: 10.1056/NEJMc1913327

Purchase this article
Print Subscriber? Activate your online access.

[PRV's Eligibility]


To be eligible for a voucher, the drug or vaccine must satisfy the following criteria.

- Treat one of the following diseases:
  - Blinding trachoma
  - Buruli Ulcer
  - Chagas (FDA added in 2015)
  - Chikungunya virus disease (FDA added in 2018)
  - Cholera
  - Cryptococcal meningitis (FDA added in 2018)
  - Dengue
  - Dracunculiasis
  - Fascioliasis
  - Filoviruses (including Ebola) (Congress added in 2014)
  - Human African trypanosomiasis
  - Lassa fever (FDA added in 2018)
  - Leishmaniasis
  - Leprosy
  - Lymphatic filariasis
  - Malaria
  - Material threat medical countermeasures (Congress added in 2016)
  - Neurocysticercosis (FDA added in 2015)
  - Onchocerciasis
  - Rabies (FDA added in 2018)
  - Rare pediatric disease (Congress added in 2012)
  - Schistosomiasis
  - Soil transmitted helminthiasis
  - Tuberculosis
  - Yaws
  - Zika (Congress added in 2016)

Buruli Ulcer

- Nature Communications (2018.12.18)


nature COMMUNICATIONS

ARTICLE

https://doi.org/10.1038/s41467-018-07804-8 OPEN

Targeting the *Mycobacterium ulcerans* cytochrome bc_1:aa_3 for the treatment of Buruli ulcer

Nicole Scherr[1,2], Raphael Bieri[1,2], Sangeeta S. Thomas[3], Aurélie Chauffour[4], Nitin Pal Kalia[3], Paul Schneide[5], Marie-Thérèse Ruf[1,2], Araceli Lamelas[1,2,6], Malathy S.S. Manimekalai[7], Gerhard Grüber[7], Norihisa Ishii[8], Koichi Suzuki[8,9], Marcel Tanner[1,2], Garrett C. Moraski[10], Marvin J. Miller[11], Matthias Witschel[5], Vincent Jarlier[4,12], Gerd Pluschke[1,2] & Kevin Pethe[3,7]

- Antimicrobial Agents and Chemotherapy (2020.03.31)


AMERICAN SOCIETY FOR MICROBIOLOGY | Antimicrobial Agents and Chemotherapy

search

Advanced Search

Home Articles For Authors About the Journal Subscribe

Clinical Therapeutics

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model

Deepak V. Almeida, Paul J. Converse, Till F. Omansen, Sandeep Tyagi, Rokeya Tasneen, Jeongjun Kim, Eric L. Nuermberger

DOI: 10.1128/AAC.00259-20

Telacebec (Q203)

ARDS with viral pneumonia (Including Covid-19)

ELSEVIER

The American Journal of
PATHOLOGY
ajp.amjpathol.org

MINI-REVIEW

Eicosanoids

The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?

Bruce D. Hammock,* Weicang Wang,* Molly M. Gilligan,†‡ and Dipak Panigrahy†‡

From the Department of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California, Davis, California; and the Center for Vascular Biology Research† and the Department of Pathology,‡ Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts*



America Phathology 2020. 6

Telacebec (Q203)

ARDS with viral pneumonia (Including Covid-19)



Untreated (vehicle)



INH(15mpk)
3.3 log10 bacterial burden reduction



Telacebec (Q203) (10mpk)
3.13 log10 bacterial burden reduction





** P value <0.01 compared with vehicle group

Qurient Telacebec (Nature Medicine, 2013)

CONTENTS

Investment Highlight

Pipeline

			Originator	PCC	Non-clinical	Phase 1	Phase 2	Remark
Oncology	Axl/Mer/CSF1R triple inhibitor (Q702)	I/O	LDC					
		Lung-cancer	LDC					
	CDK7 inhibitor (Q901)	Cancer	LDC					
	iProteasome inhibitor	Cancer Auto-immune	LDC	Joint Venture in Dortmund				QLi5 Therapeutics
Anti infection	Cyt bc1 inhibitor (Telacebec/Q203)	MDR-TB	Institut Pasteur Korea					FDA PRIORITY REVIEW
		Buruli Ulcer	Institut Pasteur Korea					FDA PRIORITY REVIEW
		COVID-19	Institut Pasteur Korea					
Anti inflamation	Topical 5-LO inhibitor (Q301)	Atopic Dermatitis	Qurient Therapeutics					
	Oral 5LO inhibitor	Asthma	Qurient Therapeutics					
Immune	Q601	Immune Modulator	Qurient Therapeutics					

Project Sourcing network with **World Renowned Research Institutes**

33 Nobel Prizes

Institut Pasteur 10 Nobel Prizes

Investment Highlight

Pipeline expansion

Single asset company

QLi5 Therapeutics

- *(From left) Dr. Kiyean Nam(Qurient), Dr. Robert Huber(Max Planck Institute), Dr. Michael Hamacher(LDC) (2019.10.02)*

Establishing Joint venture with Max Planck Institute and LDC

(Jan. 2020, Based on Dortmund)

ImmunoProteasome Inhibitor

- **ImmunoProteasome Inhibitor**



- Improvement of efficacy & side effect
- Target multiple myeloma & solid tumor

- **Multiple Myeloma의 Unmet Medical Need**

Celgene's "Revlimid"

No. 1 in sales among anticancer drugs

Takeda's "Velcade"

Top 15 in sales among anticancer drugs

Narrow Therapeutic Window

Investment Highlight

Pipeline expansion

Immune Modulator

Discovery | Candidate | Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | Approval & marketing

Qurient Therapeutics

< Comparison of survival rate between H1N1 vaccination and H1N1 vaccination + Q601>




Qurient
Therapeutics